Dr. Richard Kojo Enchill, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 260 Hospital Dr, Williamson Arh, South Williamson, KY 41503 Phone: 606-237-1700 |
Javier Garcia, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 306 Hospital Dr, South Williamson, KY 41503 Phone: 606-237-1790 |
News Archive
There has been little progress in the way we treat depression and anxiety for over thirty years, but a recent study at EPFL Ecole Polytechnique Fédérale de Lausanne (EPFL) may open the door to new strategies. In an article published online February 23, 2010, in Molecular Psychiatry, researchers from two laboratories at the Brain Mind Institute at EPFL (Ecole Polytechnique Fédérale de Lausanne) explain how understanding the functioning of a molecule called MIF, or macrophage migration inhibitory factor, may change the way we treat depression.
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
At a time when there is tremendous concern about the utilization of technology at the end of life and the costs of technology, the Canadian Institutes of Health Research (CIHR) has funded a multi-center study aimed to improve end of life decision making amongst seriously ill, elderly hospitalized patients. Queen's University is one institution receiving funding for this initiative.
Common infections are associated with a significantly higher chance of stroke in children, but routine vaccinations may help decrease risk, according to preliminary research (abstract 39) presented at the American Stroke Association's International Stroke Conference 2014.
Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.
› Verified 2 days ago